Compass CTX-471 (Advanced or Metastatic Cancer)

What is the Purpose of this Study?

We are doing this study to find out if an investigational drug, CTX-471, is safe and effective against your cancer.

What is the Condition Being Studied?

Metastatic or locally advanced cancer that did not respond to prior treatment with a PD-1 or PD-L1 inhibitor

Who Can Participate in the Study?

Adults who have metastatic or locally advanced cancer who:

  • Did not respond to prior treatment with a PD-1 or PD-L1 inhibitor
  • Have not had other systemic anticancer therapy
Age Group
Adults

What is Involved?

If you choose to join this study, you will:

  • Have an infusion of the study drug (CTX-471) once every 2 weeks
  • Have a tumor biopsy
  • Have an eye exam
  • Have physical exams, blood and urine tests
  • Have imaging scans (CT and/or MRI)
  • Have tests of your heart (ECG)

Study Details

Full Title
A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 Administered Either as a Monotherapy or in Combination with Pembrolizumab in Patients with Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies
Principal Investigator
Headshot of Niharika Bansal Mettu
Associate Professor of Medicine
Protocol Number
IRB: PRO00103011
NCT: NCT03881488
Phase
Phase I
ClinicalTrials.gov
Enrollment Status
OPEN TO ACCRUAL